Filing Flows › Lifecore Biomedical (LFCR) › Guidance & outlook
Lifecore Biomedical (LFCR) guidance and outlook
Lifecore Biomedical's 10-Q filed Nov 4, 2026 makes 4 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results.
- Lifecore expects to further improve efficiencies and productivity through additional procurement and operational strategies that will build upon the new capabilities and information available from our ERP system.
- Lifecore expects this system to strengthen inventory control, support sharper financial management, and help reduce costs as the company grows.
- There can be no assurance that additional funds, if required, will be available to the Company on favorable terms, if at all.
Lifecore Biomedical's latest quarter
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart follows the revenue to costs, profit and cash.
Questions
What does Lifecore Biomedical expect?
While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Lifecore expects to further improve efficiencies and productivity through additional procurement and operational strategies that will build upon the new capabilities and information available from our ERP system. Lifecore expects this system to strengthen inventory control, support sharper financial management, and help reduce costs as the company grows.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.